Ondine Biomedical Inc – Steriwave now available through NHS Supply Chain

Vancouver, Canada / ACCESSWIRE / June 21, 2024 / Ondine Biomedical Inc. (LON:OBI), a leader in light-activated antimicrobial treatments, announced that its Steriwave® nasal photodisinfection is now available through the NHS Supply Chain. This development simplifies procurement for NHS hospitals in England and Wales. This marks the first availability of a light-activated antimicrobial through the NHS Supply Chain, which manages healthcare product supply to NHS organizations.

Steriwave is a revolutionary treatment that eliminates pathogens without causing antimicrobial resistance (AMR). It replaces the traditional antibiotic mupirocin, enhancing patient compliance and preventing healthcare-associated infections (HAIs).

In March 2024, Mid Yorkshire Teaching NHS Trust was the first in the UK to adopt Steriwave for hip and knee surgery patients. Dr. Stuart Bond emphasized the breakthrough in preventing surgical site infections (SSIs). The trust continues collaborating on a health economic analysis expected to support wider NHS adoption.

SSIs affect one in 20 NHS surgical patients and cost NHS England over £2 billion annually. Steriwave uses a photosensitive microbial stain and red light to destroy nasal pathogens in a five-minute treatment without triggering AMR. The technology is proven to reduce post-surgical infection rates, improve outcomes, reduce antibiotic use, and save costs.